FIU takes an interdisciplinary approach to neuroscience research (FIU - Florida International University)

Edit Public Technologies 11 May 2016
(Source. FIU - Florida International University). Photo by Doug Garland '10. The brain is the most complex organ in the human body ... It controls the way we think ... Until now ... Andrew Schally, the Nobel Prize-winning director of The Endocrine, Polypeptide and Cancer Institute, to deliver cancer-fighting peptides to currently incurable gliobastoma tumors in the brain, a pinpoint treatment that minimizes collateral damage to healthy cells. ♦....

Soileau Named to Florida Inventors Hall of Fame (University of Central Florida)

Edit Public Technologies 24 Mar 2016
(Source. University of Central Florida). MJ Soileau, vice president for UCF's Office of Research and Commercialization, has been named to the Florida Inventors Hall of Fame ... It was his innovative research in the advancement of high-energy laser optics that earned him this recognition ... Seven inventors, including Nobel laureate Andrew Schally, are part of the 2016 inductees into the Florida Hall of Fame ... 16 in Tampa ... Original Document....

Florida Inventors Hall of Fame 2016 inductees include 2 from C. Fla.

Edit Business Journal 15 Mar 2016
Jacqueline Quinn, an environmental engineer at NASA's Kennedy Space Center, and the University of Central Florida's M.J ... The year's class of inductees also includes Nobel Laureate Andrew Schally; William Dalton, for his revolutionizing developments in cancer treatment; Yogi Goswami, for his pioneering contributions and technology development related to solar energy and indoor air… ... ....

UF microbiology professor inducted into Florida Inventors Hall of Fame (University of Florida)

Edit Public Technologies 15 Mar 2016
Joining Muzyczka as 2016 inductees are Nobel Laureate Andrew Schally of the University of Miami; Jacqueline Quinn, environmental engineer at NASA's Kennedy Space Center; William Dalton of M2Gen, a subsidiary of Moffitt Cancer Center & Research Institute for his revolutionizing developments in cancer treatment; Yogi Goswami of the University of ......

December 8, 2015 Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule and ...

Edit Public Technologies 09 Dec 2015
(Source. AEterna Zentaris Inc) December 8, 2015. Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule and Announces 2016 Corporate Objectives. Québec City, Canada, December 8, 2015 - Aeterna Zentaris Inc ... Andrew V. Schally, a recipient of the Nobel Prize, represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin....

Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule and Announces 2016 Corporate Objectives

Edit Stockhouse 08 Dec 2015
Aeterna Zentaris Inc. (NASDAQ. AEZS) (TSX ... Commenting on the announcement, David A. Dodd, Chairman, President and Chief Executive Officer of the Company, stated ... Zoptrex™ ... Macrilen™ ... Commercial Operations ... Andrew V. Schally, a recipient of the Nobel Prize, represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin....

New Study Published In PNAS Shows Biscayne's GHRH Agonists Could Increase The Feasiblity Of Beta Cell Transplants To Treat Type 1 Diabetes --New Studies from Lab of Biscayne Scientific Adviser and Nobel Laureate Dr. Andrew V. Schally Confirm Its GHRH Agonists Increase the Viability and Functionality of Beta Islet Cells in Multiple Models of Type 1 Diabetes--

Edit PR Newswire 20 Oct 2015
Andrew V. Schally, a scientific adviser to Biscayne and Nobel laureate who is a renowned endocrine researcher and drug developer ... Schally's lab reinforces his earlier research that suggests our GHRH agonists could contribute significantly to the feasibility of new approaches to treating diabetes by transplanting or otherwise enhancing the function of pancreatic beta islet cells." ... Schally's laboratory from the University of Miami....

Two Miami-based biopharmaceutical companies merge

Edit The Miami Herald 05 Oct 2015
Two young Miami-based biopharmaceutical companies, Biscayne Pharmaceuticals and Insero Health, already shared a lead investor and executive chairman, as well as office space on Biscayne Boulevard ... Dr ... Financial details of the transaction were not disclosed ... Andrew Schally, an endocrine researcher and prolific drug developer, said Reich ... ....

Biscayne Pharmaceuticals Merges With Insero Health, Adding Clinical-Stage Novel Epilepsy Program And Other CNS Assets --Insero Scientific Co-founder and Harvard Epilepsy Expert Dr. Steven Schachter Joins Biscayne as Senior Science Advisor----Drug Development Veteran Stephen Collins Is Named CEO and Launches Series B Financing--

Edit PR Newswire 05 Oct 2015
MIAMI BEACH, Fla., Oct ... Stephen Collins, MD, PhD, formerly Chief Executive Officer of Insero Health, has become President and CEO of Biscayne Pharmaceuticals ... Financial details of the transaction were not disclosed ... and over 50 million people worldwide ... Andrew V. Schally, discovered that cancer cells also have GHRH receptors and produce GHRH on their own ... Reich ... Andrew Schally, a renowned endocrine researcher and prolific drug developer ... Mr....

Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes --New Data Shows a Substantial Proportion of Hormone Receptor Positive, HER2 Positive and Triple Negative Breast Cancers All Contain Growth Hormone-Releasing Hormone (GHRH) Receptors----Suggests Biscayne's Novel GHRH Blockers May Be Broadly Effective across Different Breast Cancer Subtypes--

Edit PR Newswire 28 May 2015
Andrew V. Schally, a renowned drug researcher and Nobel laureate, discovered that cancer cells also make GHRH and have receptors for GHRH, thereby fueling their own growth ... Schally's GHRH discoveries and is developing GHRH antagonists that inhibit tumor growth by blocking the activity of the GHRH-family of receptors on cancer cells ... Andrew V. Schally, a Nobel laureate and pioneering endocrine drug developer....

VA Research Commemorates 90 Years of Health Care Innovation Focused on Improving Veterans’ Lives (National Cemetery Administration)

Edit noodls 30 Apr 2015
(Source. National Cemetery Administration). VA Research Commemorates 90 Years of Health Care Innovation Focused on Improving Veterans' Lives. April 30, 2015, 01.48.00 PM ... McDonald ... To date, the program has enrolled some 350,000 Veterans ... Andrew Schally, who received the award in 1977 for discoveries relating to hormones ... Schally is still an active VA researcher, studying cancer, diabetes and heart disease at the Miami VA Medical Center ... ###....

VA Research Commemorates 90 Years of Health Care Innovation Focused on Improving Veterans’ Lives (US Department of Veterans Affairs)

Edit noodls 30 Apr 2015
(Source. US Department of Veterans Affairs). VA Research Commemorates 90 Years of Health Care Innovation Focused on Improving Veterans' Lives. April 30, 2015, 01.48.00 PM ... McDonald ... To date, the program has enrolled some 350,000 Veterans ... Andrew Schally, who received the award in 1977 for discoveries relating to hormones ... Schally is still an active VA researcher, studying cancer, diabetes and heart disease at the Miami VA Medical Center....

Biscayne Pharmaceuticals closes $3.4 million funding round

Edit The Business Review 20 Jan 2015
Jan 20, 2015, 1.37pm EST. Send this to a friend. Thank you for sharing. Your email has been sent. Email address of friend (insert comma between multiple addresses).. Your email address.. Copy Me. Add a brief note.. Send Email Sending Close. Mark Freerks. Samuel Reich, Dr. Joshua Hare and Dr. Andrew Schally at the Biomedical Research Building on the campus of the University of Miami Miller School of Medicine in 2013 ... See Also ... Related links.. , ... ... ... ....
×